Clinical Movement

Wilson Disease & NBIA

Wilson Disease & NBIA

What Do You Need to Know?

  • Wilson disease: AR, ATP7B gene (chromosome 13), copper transport defect → accumulation in liver and brain
  • Diagnosis: low ceruloplasmin, elevated 24-hour urine copper (>100 µg), Kayser-Fleischer rings on slit-lamp, MRI “face of the giant panda” in midbrain
  • PKAN: PANK2 gene (AR), “eye-of-the-tiger” sign on MRI (globus pallidus), childhood-onset dystonia + pigmentary retinopathy
  • Manganese toxicity: T1 hyperintensity in globus pallidus (not T2), parkinsonism with “cock-walk” gait, no levodopa response
  • Screen for Wilson disease in ALL young patients (<50 yr) with unexplained movement disorders — treatable and fatal if missed
🚩 Don’t Miss — Test-Day Priorities
  • Wilson = ATP7B, AR, chromosome 13: impaired biliary copper excretion; presents 5–40 yr (hepatic earlier ~11, neurologic later ~20).
  • Screen EVERY patient <50 yr with unexplained movement disorder, psychiatric change, or chronic hepatitis — Wilson is treatable and fatal if missed.
  • Coombs-negative hemolytic anemia + acute liver failure + low ALP : bilirubin ratio (<4) + AST : ALT >2.2: fulminant Wilson until proven otherwise → urgent transplant evaluation.
  • Wing-beating tremor + dysarthria + risus sardonicus dystonia + juvenile parkinsonism: classic neuro-Wilson tetrad.
  • Kayser-Fleischer rings: ~95–100% of NEUROLOGIC Wilson; only ~50–60% of hepatic-only; requires SLIT-LAMP (not naked eye). Sunflower cataract = lens copper.
  • Diagnostic triad: LOW ceruloplasmin (<20; falsely normal in inflammation/estrogen) + 24-hr urinary copper >100 µg (≥40 raises suspicion) + KF rings. Free Cu >25 µg/dL. Hepatic Cu >250 µg/g dry wt = gold standard. Use Leipzig score ≥4.
  • “Face of the giant panda” = T2 midbrain (red nuclei = eyes, SNpr = ears, superior colliculus = chin); “double panda” adds pontine tegmentum sign.
  • Treatment: D-penicillamine (paradoxical neuro worsening 10–50% — many prefer TRIENTINE first-line for neuro Wilson) → ZINC for maintenance/presymptomatic; liver transplant corrects the hepatic ATP7B defect and is indicated for fulminant hepatic failure or decompensated cirrhosis (neurologic recovery is variable — transplant is not a guaranteed neurologic cure). Lifelong therapy; continue chelation in pregnancy with specialist dose adjustment (stopping anticopper therapy risks relapse). Screen all first-degree relatives.
  • “Eye-of-the-tiger” sign (T2 GP hypointensity with central hyperintensity) = PKAN (PANK2, AR); chelation NOT helpful; deferiprone trialed; DBS-GPi for dystonia.
  • Classic PKAN child: dystonia + pigmentary retinopathy + acanthocytosis + cognitive decline, onset <6 yr.
  • Neuroferritinopathy (FTL, AD) is the only AD NBIA — adult chorea-dystonia, LOW serum ferritin (paradoxical), cavitating putamen.
  • Aceruloplasminemia (CP, AR): adult diabetes + retinal degeneration + movement disorder; ceruloplasmin ~0 (vs Wilson’s low-normal); iron (not copper) overload; microcytic anemia.
  • BPAN (WDR45, X-linked dominant): female intellectual disability + Rett-like features + seizures → biphasic adult dystonia-parkinsonism; SN “halo sign” on T1.
  • MPAN (C19orf12, AR): childhood/young-adult dystonia + spasticity + optic atrophy + motor neuron features.
  • Kufor-Rakeb (ATP13A2, AR): juvenile parkinsonism + spasticity + supranuclear gaze palsy + mini-myoclonus; early levodopa-responsive then complications.
  • Manganese: T1 bright GP (not T2 dark), “cock-walk” gait, no levodopa response, normal DaTSCAN; remove from exposure.
🔍 Buzzwords & Pathognomonic FindingsClinical · Imaging · Genetics / pathology / treatment
Clinical phenotype
  • Wing-beating tremor (proximal high-amplitude postural tremor of outstretched arms) → Wilson disease
  • Risus sardonicus / sardonic grin orofacial dystonia + drooling + dysarthria in a young adult → Wilson disease
  • Coombs-negative hemolytic anemia + acute liver failure in a young patientFulminant Wilson
  • Juvenile parkinsonism + psychiatric/behavioral decline + chronic hepatitisWilson disease
  • Childhood dystonia + pigmentary retinopathy + acanthocytosisPKAN (classic)
  • Palilalia + psychiatric features + later-onset dystoniaPKAN (atypical)
  • Adult-onset chorea-dystonia, AD inheritanceNeuroferritinopathy
  • Adult diabetes + retinal degeneration + movement disorder + microcytic anemiaAceruloplasminemia
  • Girl with intellectual disability + Rett-like features + seizures → biphasic adult dystonia-parkinsonismBPAN (WDR45)
  • Childhood dystonia + spasticity + optic atrophy + motor neuron signsMPAN (C19orf12)
  • Juvenile parkinsonism + supranuclear gaze palsy + mini-myoclonus + spasticityKufor-Rakeb (ATP13A2)
  • “Cock-walk” toe-strutting gait + manganese madness, no levodopa responseManganese toxicity
Imaging signs
  • “Face of the giant panda” sign on T2 midbrainWilson disease
  • “Face of the miniature/double panda” (pontine tegmentum)Wilson disease
  • T2/FLAIR putaminal hyperintensity (most common Wilson finding)Wilson disease
  • Kayser-Fleischer ring at corneal limbus (Descemet’s membrane)Wilson disease
  • Sunflower cataractWilson disease (lens copper)
  • “Eye-of-the-tiger” sign — T2 GP hypointensity with central hyperintensityPKAN (PANK2)
  • Cavitating/cystic basal ganglia lesions with low ferritinNeuroferritinopathy
  • SN “halo sign” — T1 hyperintense halo with central hypointensity, plus GP/SN iron on T2*/SWIBPAN
  • T1 hyperintensity in bilateral globus pallidusManganese toxicity (also chronic liver disease, TPN)
  • Cerebellar atrophy + axonal spheroidsPLAN/INAD (PLA2G6)
Genetics / pathology / treatment
  • ATP7B (chromosome 13q14), AR, P-type copper ATPaseWilson disease (H1069Q most common European mutation)
  • Low ceruloplasmin + 24-hr urine Cu >100 µg + hepatic Cu >250 µg/g + Leipzig ≥4Wilson disease
  • ALP : total bilirubin <4 + AST : ALT >2.2Fulminant Wilson
  • D-penicillamine paradoxical neurologic worsening (10–50%)Wilson — prefer trientine first-line for neuro disease
  • Zinc → intestinal metallothionein blocks copper absorptionWilson maintenance
  • Liver transplant corrects the ATP7B hepatic defect (indicated for fulminant failure or decompensated cirrhosis; neurologic recovery is variable — NOT a guaranteed neurologic cure) → Wilson disease
  • PANK2 (20p13), AR — coenzyme A synthesis defect; formerly Hallervorden-SpatzPKAN
  • FTL gene, autosomal DOMINANT (only AD NBIA), LOW serum ferritinNeuroferritinopathy
  • CP gene, AR; absent ceruloplasmin (~0) with brain/systemic IRON overloadAceruloplasminemia
  • WDR45, X-linked dominant; biphasic courseBPAN
  • C19orf12, AR; GP + SN iron with optic atrophyMPAN
  • ATP13A2, AR; early levodopa response with motor complicationsKufor-Rakeb
  • PLA2G6, AR; axonal spheroids on biopsyPLAN/INAD
  • Normal DaTSCAN with parkinsonism (post-synaptic GP injury)Manganese toxicity
  • Chelation (deferiprone) trialed; DBS-GPi for dystonia; chelation NOT helpful in PKAN copper-styleNBIA management
Wilson Disease

Genetics & Pathophysiology

  • Gene: ATP7B (chromosome 13q14) — copper-transporting P-type ATPase
  • Inheritance: autosomal recessive; carrier frequency ~1:90; prevalence ~1:30,000
  • >500 mutations described; most patients are compound heterozygotes; H1069Q most common in Europeans
  • Normal: ATP7B incorporates copper into ceruloplasmin and excretes excess into bile
  • Wilson: impaired biliary copper excretion → hepatocyte accumulation → liver injury → copper released into blood → deposits in basal ganglia (putamen), cornea (KF rings), kidneys
  • Free (non-ceruloplasmin-bound) copper causes oxidative damage via Fenton reaction
  • Age: typically 5–40 years; hepatic presentation younger (~11 yr), neurologic later (~20 yr)

Neurologic Features

  • Dystonia: most common movement disorder; often orofacial → “risus sardonicus” (sardonic grin)
  • Tremor: classic “wing-beating” tremor (proximal, high-amplitude postural tremor of outstretched arms)
  • Parkinsonism: rigidity, bradykinesia, hypomimia — may mimic juvenile-onset PD
  • Dysarthria: often the first neurologic symptom; mixed cerebellar-extrapyramidal pattern
  • Drooling: from orofacial dystonia + impaired swallowing
  • Cerebellar signs: ataxia, intention tremor in some patients
  • Chorea: less common but may occur, especially early in disease
  • Neurologic Wilson nearly always has underlying hepatic copper accumulation, even if liver is clinically silent

Psychiatric & Hepatic Features

  • Psychiatric (30–50%): personality changes, depression, impulsivity, academic decline — may precede neurologic signs by years
  • Chronic hepatitis/cirrhosis: may be asymptomatic; mimics autoimmune hepatitis
  • Fulminant liver failure: Coombs-negative hemolytic anemia + acute liver failure + very low ceruloplasmin = Wilson until proven otherwise
  • Alkaline phosphatase characteristically low relative to bilirubin in fulminant Wilson

Ophthalmologic Findings

  • Kayser-Fleischer rings: copper in Descemet’s membrane; golden-brown ring at limbus
  • Present in ~95% with neurologic Wilson, ~50% with hepatic-only presentation
  • Requires slit-lamp — not always visible to the naked eye
  • Sunflower cataracts: copper deposits in lens; less common
Clinical Pearl
  • Coombs-negative hemolytic anemia + acute liver failure in a young patient = Wilson disease until proven otherwise. This is a medical emergency requiring urgent transplant evaluation. Hemolysis results from massive copper release from necrotic hepatocytes.
Wilson Disease — Diagnosis & Treatment

Laboratory Studies

TestResultKey Notes
Serum ceruloplasmin<20 mg/dLLow in ~85–90%; can be falsely normal in inflammation/pregnancy/estrogen (acute-phase reactant)
24-hr urine copper>100 µg/dayOne of the most useful screening tests — no single test is definitive. Current practice integrates ceruloplasmin, 24-hr urine copper, KF rings, MRI findings, ATP7B genetic testing, and the Leipzig score (composite scoring system). ≥40 µg/day raises suspicion; >100 µg/day is the classic threshold (lower cutoffs increasingly used, especially in pediatrics)
Free serum copper>25 µg/dLCalculated: total Cu − (3 × ceruloplasmin); toxic fraction
Total serum copperLow/low-normalParadoxically low because ceruloplasmin-bound Cu (90% of total) is reduced
Hepatic copper>250 µg/g dry wtGold standard; requires liver biopsy; normal <50 µg/g
ATP7B sequencingBiallelic variantsConfirmatory; useful for family screening

Leipzig Score

  • Combines KF rings, neurologic symptoms, ceruloplasmin, hemolytic anemia, liver copper, urinary copper, mutation analysis
  • ≥4: diagnosis highly likely | 3: possible | ≤2: unlikely

MRI Brain

  • T2/FLAIR hyperintensity: putamen (most common), globus pallidus, caudate, thalamus, midbrain, pons
  • “Face of the giant panda”: T2 axial midbrain — tegmental T2 hyperintensity with preserved red nuclei forming the “eyes” and preserved (hypointense) substantia nigra pars reticulata forming the lateral borders/“ears”; the superior colliculus forms the “chin”
  • “Face of the miniature panda”: seen in pontine tegmentum (less commonly tested)
  • T1 hyperintensity in GP may also be seen, reflecting manganese deposition from associated hepatic dysfunction (not copper itself)
  • Cortical and white matter changes in advanced disease

Treatment

  • D-Penicillamine: chelator; mobilizes copper for urinary excretion; side effects: nephrotoxicity, marrow suppression, lupus-like syndrome, neurologic worsening in ~10–20% (up to ~50% in some series) at initiation
  • Trientine: alternative chelator; better tolerated; preferred by many as first-line for neurologic Wilson
  • Zinc: induces intestinal metallothionein → blocks copper absorption; used for maintenance or presymptomatic patients; separate zinc from chelators and food by ≥1 hour
  • Liver transplant: for fulminant hepatic failure or decompensated cirrhosis; corrects the hepatic ATP7B defect (new liver has functional ATP7B). Neurologic recovery is variable — transplant is not a guaranteed neurologic cure.
  • Diet: avoid liver, shellfish, chocolate, mushrooms, nuts (high copper)
  • Screen all first-degree relatives; treatment is lifelong — non-compliance causes rapid deterioration
  • Pregnancy: continue chelation with specialist dose adjustment (typically reduced D-penicillamine/trientine dose to limit fetal copper deficiency); zinc may be continued at usual dose. Stopping anticopper therapy in pregnancy risks maternal hepatic and neurologic relapse.
💎 Board Pearl
  • Low ceruloplasmin + elevated 24-hr urine copper + KF rings = classic triad. Ceruloplasmin alone is insufficient — normal in 10–15% of Wilson patients and low in carriers/nephrotic syndrome.
  • “Face of the giant panda” on midbrain MRI is highly specific but not always present. Putaminal T2 hyperintensity is the most common finding.
  • Penicillamine can paradoxically worsen neurologic symptoms early in treatment due to copper mobilization. Many experts prefer trientine first-line for neurologic Wilson.
  • Low alkaline phosphatase relative to total bilirubin (ALP : total bilirubin ratio <4) in a patient with acute liver failure is a classic clue to fulminant Wilson disease — combined with an AST : ALT ratio >2.2, the two-ratio profile has high specificity. Confirm with serum free copper, KF rings, and 24-hr urine copper; consider urgent transplant evaluation.
NBIA Overview
  • Neurodegeneration with brain iron accumulation (NBIA): group of inherited disorders with progressive iron deposition in basal ganglia
  • Common features: progressive dystonia, spasticity, parkinsonism, cognitive decline
  • MRI hallmark: T2/T2* hypointensity (dark signal) in globus pallidus and/or substantia nigra
  • Most are autosomal recessive; exceptions: neuroferritinopathy (AD) and BPAN (X-linked)
  • PKAN is the most common subtype (~50% of NBIA cases)
PKAN (Pantothenate Kinase-Associated Neurodegeneration)

Genetics

  • Gene: PANK2 (chromosome 20p13) — pantothenate kinase 2, rate-limiting enzyme in coenzyme A synthesis
  • Inheritance: autosomal recessive
  • Formerly Hallervorden-Spatz disease (name abandoned; still appears in older references)
  • Proposed mechanism: PANK2 deficiency → cysteine accumulation + cysteine-iron chelates → oxidative damage and iron deposition in GP (mechanism not fully established)

Classic Form (<6 years)

  • Progressive dystonia (often oromandibular), spasticity, gait difficulty
  • Pigmentary retinopathy: important diagnostic clue in classic form
  • Cognitive decline, dysarthria, dysphagia
  • Acanthocytosis on peripheral blood smear in some patients
  • Rapid progression; most wheelchair-bound within 10–15 years of onset

Atypical Form (2nd–3rd Decade)

  • Prominent speech difficulty (palilalia, dysarthria) and psychiatric symptoms
  • Slower progression than classic form
  • Pigmentary retinopathy less common

MRI: Eye-of-the-Tiger Sign

  • T2 MRI: bilateral GP hypointensity (dark/iron) with central hyperintensity (bright/gliosis) → resembles a tiger’s eye
  • Highly sensitive (reported >95% in some series, but not universal) and highly specific for PANK2; central hyperintensity may diminish over time as gliosis is replaced by iron
  • May be present before symptom onset
💎 Board Pearl
  • “Eye-of-the-tiger” sign on T2 MRI = PKAN (PANK2 mutation) — classic boards image. Bilateral globus pallidus hypointensity with central hyperintensity is highly characteristic of PKAN (rare mimics have been described in other NBIAs, neuroferritinopathy, and a few non-NBIA disorders).
  • PKAN + pigmentary retinopathy + acanthocytosis in a child with progressive dystonia = classic board vignette.
Other NBIA Subtypes
DisorderGeneInheritanceKey FeaturesDistinguishing Clue
NeuroferritinopathyFTLADAdult-onset chorea/dystonia; cavitating basal ganglia lesionsLow serum ferritin (especially in males; may be normal in premenopausal females); only AD NBIA; cystic BG on MRI
AceruloplasminemiaCPARDiabetes + retinal degeneration + movement disorder; onset 40–60 yrLOW serum copper (distinguishes from primary copper disorder); microcytic anemia; iron overload (not copper); absent ceruloplasmin
PLAN/INADPLA2G6ARInfantile neuroaxonal dystrophy; 6 mo–3 yr; psychomotor regressionCerebellar atrophy; axonal spheroids; also adult dystonia-parkinsonism
MPANC19orf12ARChildhood/young adult; dystonia, spasticity, optic atrophyGP + SN iron; motor neuron features may coexist
BPANWDR45X-linkedStatic childhood encephalopathy → rapid adult decline (dystonia-parkinsonism, dementia)Biphasic course; T1 hyperintense halo with central hypointensity in SN (“halo sign”); iron in both SN and GP on T2*/SWI
Kufor-RakebATP13A2ARJuvenile atypical parkinsonism, spasticity, supranuclear gaze palsy; variable iron accumulation on MRIInitial levodopa response with early motor complications; mini-myoclonus
💎 Board Pearl
  • Neuroferritinopathy is the only AD NBIA — low serum ferritin is the clue.
  • Aceruloplasminemia vs. Wilson: both have low/absent ceruloplasmin, but aceruloplasminemia has iron overload (not copper) with diabetes and retinal degeneration.
  • BPAN: biphasic course (static childhood encephalopathy → rapid adult-onset decline) is the key distinguishing feature.
Manganese Toxicity

Exposure Sources

  • Occupational: welders, miners, smelter workers, dry battery manufacturers
  • Other: total parenteral nutrition (TPN), chronic liver disease, methcathinone (ephedrone) abuse, contaminated well water

Clinical Features

  • Manganism: parkinsonism with prominent gait disorder
  • “Cock-walk” gait: walking on toes with strutting pattern — highly suggestive
  • Dystonia, bradykinesia, rigidity; rest tremor less prominent than PD
  • Early psychiatric symptoms: irritability, emotional lability, hallucinations (“manganese madness”)
  • No levodopa response — pathology is post-synaptic (GP), not presynaptic (SN as in PD)

Imaging & Management

  • T1 hyperintensity in bilateral globus pallidus — hallmark finding; manganese is paramagnetic (shortens T1)
  • T1 signal normalizes after exposure cessation (unlike permanent iron deposition in NBIA)
  • DaTSCAN: normal (presynaptic dopaminergic neurons intact) — distinguishes from PD
  • Elevated blood and urine manganese levels (may not correlate with clinical severity)
  • Treatment: remove from exposure (most important step); chelation (CaNa2-EDTA, para-aminosalicylic acid) has variable results (evidence limited; mainstay is exposure removal)
  • Neurologic deficits may be partially irreversible despite exposure cessation
💎 Board Pearl
  • T1 hyperintensity in GP = manganese. Manganese = T1 bright; iron (NBIA) = T2 dark. Do not confuse them.
  • Manganese vs. PD: manganese → “cock-walk” gait, targets GP (not SN), no levodopa response, normal DaTSCAN. PD → SN degeneration, levodopa-responsive, abnormal DaTSCAN.

References

  • European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Wilson’s disease. J Hepatol. 2012;56(3):671-685.
  • Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 2003;23(3):139-142.
  • Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med. 2003;348(1):33-40.
  • Gregory A, Hayflick SJ. Neurodegeneration with brain iron accumulation. Folia Neuropathol. 2005;43(4):286-296.
  • Hogarth P. Neurodegeneration with brain iron accumulation: diagnosis and management. J Mov Disord. 2015;8(1):1-13.
  • Ala A, Walker AP, Ashkan K, et al. Wilson’s disease. Lancet. 2007;369(9559):397-408.
  • Racette BA, Aschner M, Guilarte TR, et al. Pathophysiology of manganese-associated neurotoxicity. Neurotoxicology. 2012;33(4):881-886.
  • Lorincz MT. Neurologic Wilson’s disease. Ann N Y Acad Sci. 2010;1184:173-187.
🔒

Continue reading — sign in

The full note has more clinical pearls, tables, and board-focused tips. Free account, no fee.